Maxigen Biotech Inc (1783) — Capital Reinvestment Ratio
Latest as of March 2026:
0.13x
Maxigen Biotech Inc (1783) has a Capital Reinvestment Ratio of 0.13x as of March 2026, meaning it reinvests 0% of its operating cash flow (NT$79.84 Million) in capital expenditures (NT$10.47 Million). See Maxigen Biotech Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.13x
Capex / Operating Cash Flow
Operating Cash Flow
NT$79.84 Million
TWD
Capital Expenditures
NT$10.47 Million
TWD
Data as of
Mar 2026
Most recent filing
Maxigen Biotech Inc Capital Reinvestment Ratio (2009–2025)
This chart tracks Maxigen Biotech Inc's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Maxigen Biotech Inc (2009–2025)
Year-by-year Capital Reinvestment Ratio for Maxigen Biotech Inc from 2009 to 2025. For live market cap and broader valuation context, see Maxigen Biotech Inc (1783) total market value.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.28x | NT$290.22 Million | NT$82.63 Million | ▲ +167.3% |
| 2024 | 0.11x | NT$298.22 Million | NT$31.77 Million | ▼ -18.7% |
| 2023 | 0.13x | NT$171.20 Million | NT$22.44 Million | ▲ +143.6% |
| 2022 | 0.05x | NT$268.34 Million | NT$14.44 Million | ▼ -59.0% |
| 2021 | 0.13x | NT$117.59 Million | NT$15.45 Million | ▼ -13.8% |
| 2020 | 0.15x | NT$74.39 Million | NT$11.34 Million | ▼ -39.4% |
| 2019 | 0.25x | NT$94.42 Million | NT$23.74 Million | ▲ +112.0% |
| 2018 | 0.12x | NT$170.58 Million | NT$20.23 Million | ▼ -83.2% |
| 2017 | 0.70x | NT$41.18 Million | NT$29.01 Million | ▼ -66.4% |
| 2016 | 2.09x | NT$34.72 Million | NT$72.71 Million | ▲ +487.8% |
| 2012 | 0.36x | NT$17.53 Million | NT$6.24 Million | ▼ -9.9% |
| 2009 | 0.40x | NT$19.27 Million | NT$7.62 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow